Immuneering Corporation
IMRX
$5.05
-$0.40-7.34%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 7.59% | -1.60% | -3.70% | -2.72% | -4.07% |
| Depreciation & Amortization | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -7.33% | 3.83% | 5.96% | 8.76% | 9.69% |
| Operating Income | 7.33% | -3.83% | -5.96% | -8.76% | -9.69% |
| Income Before Tax | 8.21% | -7.63% | -10.81% | -14.03% | -14.15% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 8.21% | -7.63% | -10.81% | -14.03% | -14.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 8.21% | -7.63% | -10.81% | -14.03% | -14.15% |
| EBIT | 7.33% | -3.83% | -5.96% | -8.76% | -9.69% |
| EBITDA | 7.32% | -3.89% | -6.01% | -8.79% | -9.69% |
| EPS Basic | 32.05% | 9.32% | 0.66% | -5.95% | -7.79% |
| Normalized Basic EPS | 32.17% | 9.48% | 1.68% | -4.83% | -6.86% |
| EPS Diluted | 32.05% | 9.32% | 0.66% | -5.95% | -7.79% |
| Normalized Diluted EPS | 32.17% | 9.48% | 1.68% | -4.83% | -6.86% |
| Average Basic Shares Outstanding | 46.58% | 20.40% | 12.63% | 8.17% | 5.54% |
| Average Diluted Shares Outstanding | 46.58% | 20.40% | 12.63% | 8.17% | 5.54% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |